Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Earnings analysis
Liquidia Corp · LQDA · Third quarter 2026

Liquidia's YUTREPIA hits $222.7M in Q3 as a $389.7M settlement charge clears the courtroom

Liquidia's net product sales rose 31% sequentially and adjusted EBITDA reached $140.5M, but the United Therapeutics settlement removes PH-ILD from YUTREPIA's label and commits cash through 2027.

17 Nov 2026 · CompePharma editorial
$222.7 millionYUTREPIA net product sales, Q3 2026
up 31%Sequential growth vs. Q2 2026
$140.5 millionNon-GAAP adjusted EBITDA
$236.3 million ($2.64)Net loss (per share)
$389.7 millionLitigation settlement charge
$396.1 millionCash and cash equivalents, Sept. 30, 2026

The quarter in numbers

Liquidia reported net product sales of $222.7 million for the third quarter ended September 30, 2026, up 31% from the second quarter of 2026. A year earlier the figure was $51.7 million. The company attributed the $171.0 million year-over-year increase to higher YUTREPIA volume. It began shipping in the U.S. in June 2025, after full FDA approval in May 2025.

The GAAP result was a net loss of $236.3 million, or $2.64 per basic and diluted share, against a loss of $3.5 million, or $0.04 per share, in the third quarter of 2025. The gap is the $389.7 million litigation settlement charge. Excluding that charge, the company said, YUTREPIA sales produced a fifth consecutive quarter of rising non-GAAP adjusted EBITDA, which was $140.5 million. An income tax benefit of $30.1 million partly cushioned the loss; there was none in the prior-year quarter.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.

More CP+ Earnings analysisAll →
CP+ Earnings analysis
Tonix Pharmaceuticals Holding Corp. · TNXP · Third quarter 2026

Tonix's TONMYA reaches $15M, but a $163M cash pile and a Paragraph IV filing frame the debate

approximately $17.2 million (vs $3.3 million in Q3 2025)Net product revenue, Q3 2026approximately $15.0 million, up 37% from Q2TONMYA net sales, Q3 2026$53.3 million, or $2.89 per shareNet loss to common, Q3 2026

Third-quarter net product revenue rose to about $17.2M, yet opex of $72.7M and a runway only into early Q3 2027 mean financing and patent litigation loom over the launch.

19 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
ADC Therapeutics SA · ADCT · Third quarter 2026

ADC Therapeutics: volume-led sales and deeper cost cuts, as recapitalisation shifts focus to ASH

$21.0 million (vs $15.8 million in Q3 2025)Q3 2026 net product revenue$36.1 million, a 24% reductionQ3 total operating expenses$25.3 million, or $0.16 per share (vs $41.0 million, or $0.30)Q3 net loss

Q3 net product revenue of $21.0M and a 29% cut in adjusted opex narrowed the loss, while an October restructuring extended the company's expected cash runway into 2029.

18 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
Inhibrx Biosciences, Inc. · INBX · Third quarter 2026

Inhibrx's Q3: Debt and launch prep push losses up as chondrosarcoma review looms

$2.0 millionQ3 2026 revenue$38.7 million, or $2.46 per shareQ3 2026 net loss$26.0 million vs $28.5 million in Q3 2025Q3 R&D expense

A $2.0 million Pfizer licence fee barely dented a $38.7 million net loss as interest costs and pre-commercial spend rose while R&D fell and the balance sheet moved into deficit.

18 Nov 2026 · CompePharma editorial